Código QR (código de barras bidimensional)

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy

BackgroundRespiratory Syncytial Virus (RSV) is the leading cause of hospitalizations in infants. The approval of nirsevimab, a long-acting monoclonal antibody, has extended the potential for RSV prophylaxis to all infants. This study assesses the cost–benefit of various Nirsevimab prophylaxis strate...

Fuld beskrivelse

Na minha lista:
Principais autores: Vieri Lastrucci, Martina Pacifici, Giorgia Alderotti, Monia Puglia, Elettra Berti, Federica Barbati, Lorenzo Lodi, Silvia Boscia, Francesco Nieddu, Giuseppe Indolfi, Diego Peroni, Marco Martini, Chiara Azzari, Fabio Voller, Maria Moriondo, Silvia Ricci
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2025-07-01
Serier:Frontiers in Public Health
Fag:
respiratory syncytial virus (RSV)
immunization
prevention
nirsevimab
hospitalizations
cost–benefit analysis
Online adgang:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1604331/full
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker